IGF-1 inhibitors and lifespan extension?

Is there any studies on any drug that inhibit IGF-1 and which has shown good lifespan extension?

IGF1 receptor inhibition amplifies the effects of cancer drugs by autophagy and immune-dependent mechanisms (2021)

“Here, we report the identification of picropodophyllin (PPP), a cyclolignan alkaloid derived from the mayapple plant, as a potent inducer of autophagy that acts through the inhibition of insulin-like growth factor-1 receptor (IGF1R). When administered to tumor-bearing mice, PPP enhanced the
efficacy of immunogenic chemotherapy combined with immunotherapy and these effects relied on the induction of autophagy in malignant cells… PPP efficiently blocked IGF1-induced IGF1R autophosphorylation, the activating phosphorylation of protein kinase B (best known as AKT), the phosphorylation of MTOR, and the activity of MTOR complex 1 (MTORC1), evaluated by assessing the phosphorylation of the MTORC1 substrates p70S6K and TFEB. Inhibition of IGF1R itself or that of the signal transduction cascade acting downstream of IGF1R (the PI3K/AKT/MTOR pathway) potently stimulates autophagy as well as other stress-adaptive mechanisms. Indeed, a vast literature suggests that chronic inhibition of this pathway by caloric restriction pharmacological inhibitors or loss-of-function mutations has the capacity to extend the healthspan and lifespan in model organisms and perhaps in humans as well. PPP could be replaced by another IGF1R inhibitor, linsitinib, which has undergone evaluation in clinical trials”

IGF-1R Inhibitor Ameliorates Neuroinflammation in an Alzheimer’s Disease Transgenic Mouse Model (2020)

Clinical setbacks reduce IGF-1 inhibitors to cocktail mixers (2012, existing cancer trial)
https://doi.org/10.1038/nbt1012-906c

“AMG-479’s failure will likely be a death knell for the field of IGF-1 targeting. For the meantime,
though, it looks like industry will be looking at mechanisms other than IGF-1R inhibition
in cancer drug development”

1 Like